CBSET and our partner Cilcare are pleased to present a Safety Pharmacology Society (SPS) educational webinar Streamlining Ototoxicity Studies: From Research to Clinic, on Thursday, December 4, 2025, 8:00 AM PT/11:00 AM ET/17:00 CEST.
This webinar will explore the growing importance of auditory safety testing in the development of new therapeutics. This session is designed for researchers, toxicologists, and regulatory professionals seeking to better understand and implement auditory safety strategies from discovery through clinical development.
The session will be presented by CBSET Study Director Donald Hodges, MSc, PhD, DSP, DABT, and moderated by Raafat Fares, PhD, ERT, DABT, DSP, Chair of the SPS Training & Education Committee.
Related Publications:
Maximizing insights from nonclinical safety studies in the context of rising costs and changing regulations. Donald Hodges, Michael Stonerook, Dany Salvail, Sandrine Lemouton. Journal of Pharmacological and Toxicological Methods. Volume 128, July–August 2024, 107538.
Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Marie-Pierre Pasdelou, Lise Byelyayeva, Susanna Malmström, Sylvie Pucheu, Marie Peytavy, Hugo Laullier, Donald B. Hodges, Abraham R. Tzafriri, Gaëlle Naert. Frontiers in Molecular Neuroscience, May 2, 2024.
HEAR THIS! Potential Therapeutics for COVID-19 Should Be Tested for Auditory Safety. Michael Naimark, Director of Business Development, CBSET; Wahid Awad, PhD, Chief Business Officer, Cilcare. World Pharma Today, August 24, 2020.
Auditory Therapy, Ototoxicity, and GLP Compliance: Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve? Michael Naimark, Director of Business Development, CBSET; Marie-Pierre Pasdelou, founder and the Chief Development Officer, Cilcare. World Pharma Today, November 1, 2017.